Clinical trial · Interventional
A Study of ATG-031 in Advanced Solid Tumors or B-cell Non-Hodgkin Lymphomas
A First-in-Human Phase I Study of ATG-031 in Patients With Advanced Solid Tumors or B-cell Non-Hodgkin Lymphomas
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): The study was terminated because of sponsor's development strategy change
Summary
Brief summary (as posted)
ATG-031 study (alias: PERFORM) is a multicenter, open-label, Phase 1 study of ATG-031 in patients with advanced solid tumors or B-NHL. The study design includes a Dose Escalation Phase and a Dose Expansion Phase, and will enroll patients with advanced solid tumors (i.e., preferred tumor types) or relapsed/refractory (R/R) B-NHLs. The study's primary objective is to evaluate the safety and tolerability of ATG-031 and determine the RP2D(Refered Phase II dose) of ATG-031.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Solid Tumors | Solid Neoplasm | CURATED_BROADER | 0.80 |
| B-cell Non-Hodgkin Lymphomas | B-Cell Non-Hodgkin Lymphoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| ATG-031 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (8)
- type
- ACTIVE_COMPARATOR
- label
- ATG-031 dose level 1
- description
- Patients with advanced solid tumors or B-cell non-Hodgkin lymphomas will be enrolled in the Dose-Escalation Phase. Dose level is 0.03 mg/kg
- interventionNames
- Drug: ATG-031
- type
- ACTIVE_COMPARATOR
- label
- ATG-031 dose level 2
- description
- Patients with advanced solid tumors or B-cell non-Hodgkin lymphomas will be enrolled in the Dose-Escalation Phase. Dose level is 0.1 mg/kg
- interventionNames
- Drug: ATG-031
- type
- ACTIVE_COMPARATOR
- label
- ATG-031 dose level 3
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Key Inclusion Criteria: 1. Histological or cytologically confirmed advanced solid tumor or B-NHL which have relapsed from or been refractory to all locally available standard therapies. 2. Adequate hepatic function: 1. AST and ALT ≤ 2.5×times ULN (≤ 5 × ULN if liver metastases). 2. Total bilirubin ≤ 1.5×ULN (except Gilbert syndrome). 3. Lipase and amylase ≤ 2×ULN. 3. Adequate renal function: calculated creatinine clearance of ≥ 40 mL/min using the Cockroft- Gault formula. 4. Adequate bone marrow function without growth factors or blood transfusion within 7 days of the first dose of study treatment. 1. Absolute neutrophil count (ANC) ≥ 1.5×109/L. 2. Platelet count ≥ 100×109/L. 3. Hemoglobin ≥ 90 g/L. Key Exclusion Criteria: 1. Patients with CNS malignancies, except those who are clinically stable for ≥ 4 weeks and off corticosteroids following prior surgery, whole-brain radiation, or stereotactic radiosurgery. 2. Received any other investigational product or prior systemic anticancer therapy including chemotherapy, immunotherapy, radiotherapy, or other anticancer within 21 days prior to first dose of study 3. Grade ≥3 irAEs or irAEs that lead to discontinuation of prior immunotherapy.8. Other primary malignancies developed within 5 years prior to the first dose of the study treatment 4. Other primary malignancies developed within 5 years prior to the first dose of the study treatment 5. Have active or previous autoimmune diseases that are likely to recur or are at risk of such diseases judged by the investigator. 6. Major cardiovascular disease 7. Active hepatitis B and/or hepatitis C (HBV-DNA or HCV-RNA detectable by local laboratory, respectively). 8. Patients with history of human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS). 9. A history of allograft organ transplantation for solid tumor or allogeneic hematopoietic stem cell transplantation for B-NHL patients). 10. Patients who are pregnant or lactating.
References
Publications (0)
Data not yet available